Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Rockville, Maryland and London (ots/PRNewswire) - - BENLYSTA (belimumab) met its primary efficacy endpoint by achieving a statistically significant improvement in patient response rate versus placebo in BLISS-52 - - First drug for lupus to reach this advanced stage of clinical development and achieve ...
mehr